Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (11,3 Mio. €): Kollaboratives Handeln und Forschen für Engagement, Beharrlichkeit und Adhärenz in Behandlung und Gesundheit Hor01.05.2025 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Kollaboratives Handeln und Forschen für Engagement, Beharrlichkeit und Adhärenz in Behandlung und Gesundheit
CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI ≥ 30 kg/m2), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden. These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care. Our strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings. This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting. Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems.
Geförderte Unternehmen:
Quelle: https://cordis.europa.eu/project/id/101192133
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: A. Menarini - Industrie Farmaceutiche Riunite - Srl, Florenz, Italien.
